Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?
GroupCenter for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine (Temple University)
Permanent link to this recordhttp://hdl.handle.net/20.500.12613/4163
MetadataShow full item record
AbstractWe have read with interest the review article by Bikdeli et al recently published in Thrombosis and Haemostasis on the priority in planning studies on the different anticoagulants in coronavirus disease 2019 (COVID-19) infection. The authors describe the characteristics of both the anticoagulants available today and in the future. Antiplatelets drugs have been also considered. Surprisingly, fondaparinux (FPX) has reached a lower priority research mean (4.89) than unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) at intermediate (7.82) or therapeutic (7.53) dosage for hospitalized ward and intensive care unit patients. We believe that properties of these drugs have been overlooked by the scientific panel of the Global COVID-19 Thrombosis Collaborative Group.
Citation to related workGeorg Thieme Verlag KG
Has partTH Open, Vol. 4, Issue 4
ADA complianceFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact email@example.com